1
|
Teixeira AL, Gregg A, Gentry MT, Gujral S, Rapp E, Oberlin L, Ajilore O, Weisenbach S, Patrick R. Cognitive Deficits in Late-Life Depression: From Symptoms and Assessment to Therapeutics. FOCUS (AMERICAN PSYCHIATRIC PUBLISHING) 2025; 23:183-194. [PMID: 40235602 PMCID: PMC11995896 DOI: 10.1176/appi.focus.20240046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/17/2025]
Abstract
Cognitive symptoms and deficits are core features of late-life depression (LLD), with an estimated 20%-50% of affected individuals meeting diagnostic criteria for mild cognitive impairment (MCI). Cognitive deficits, especially executive dysfunction, have consistently been associated with poorer treatment outcomes among people with LLD. Furthermore, distinguishing depression with cognitive complaints or cognitive impairment from the early stages of Alzheimer's disease (AD) can be challenging. Cognitive concerns are often emphasized among those with LLD, although, paradoxically, their description of memory difficulty may include detailed recall of specific memory lapses. Conversely, people with AD often have limited insight into their progressive cognitive decline, minimizing and concealing their cognitive difficulties. Neuropsychological assessment is one of the most useful means of clarifying this differential diagnosis. A subcortical cognitive pattern is commonly observed among people with LLD, including psychomotor slowing, variable attention, and executive dysfunction, which can affect memory encoding and free recall. A broad range of therapeutic approaches have been applied to older adults experiencing LLD along with cognitive symptoms, MCI, or dementia. Most studies focus on treatments to address LLD or MCI, with relatively fewer examining treatments specifically at this intersection. Nonpharmacological strategies, including aerobic exercise, cognitive remediation, and neuromodulation, are highly recommended to improve both depression and cognition. Antidepressants may have benefits for elements of cognition among people with LLD, but they have less evidence for their efficacy for people with cognitive deficits and dementia. This review provides an updated conceptual and practical framework for clinicians evaluating and treating LLD.
Collapse
Affiliation(s)
- Antonio L Teixeira
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Allison Gregg
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Melanie T Gentry
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Swathi Gujral
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Ellie Rapp
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Lauren Oberlin
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Olusola Ajilore
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Sara Weisenbach
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Regan Patrick
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| |
Collapse
|
2
|
Ahmed Y, Ferguson-Pell M, Adams K, Ríos Rincón A. EEG-Based Engagement Monitoring in Cognitive Games. SENSORS (BASEL, SWITZERLAND) 2025; 25:2072. [PMID: 40218585 PMCID: PMC11991241 DOI: 10.3390/s25072072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2025] [Revised: 03/21/2025] [Accepted: 03/21/2025] [Indexed: 04/14/2025]
Abstract
Cognitive decline and dementia prevention are global priorities, with cognitive rehabilitation games showing potential to delay their onset or progression. However, these games require sufficient user engagement to be effective. Assessing the engagement through questionnaires is challenging for the individuals suffering from cognitive decline due to age or dementia. This study aims to explore the relationship between game difficulty levels, three EEG engagement indices (β/(θ + α), β/α, 1/α), and the self-reported flow state scale score during video gameplay, and to develop an accurate machine learning algorithm for the classification of user states into high- and low-engagement. Twenty-seven participants (nine older adults) played a stunt plane video game while their EEG signals were recorded using EPOCX. They also completed the flow state scale for occupational tasks questionnaire after the easy, optimal, and hard levels of gameplay. Self-reported engagement scores significantly varied across the difficulty levels (p = 0.027), with the optimal level yielding the highest scores. Combining the three EEG indices achieved the best performance, with F1 scores of 89% (within-subject) and 81% (cross-subject). Engagement classification F1 scores were 90% for young adults and 85% for older adults. The findings provide preliminary data that supports using EEG data for engagement analysis in adults and older adults.
Collapse
Affiliation(s)
- Yusuf Ahmed
- Department of Occupational Therapy, Faculty of Rehabilitation Medicine, University of Alberta, 8205 114 St NW, Edmonton, AB T6G 2G4, Canada
- Department of Biomedical Engineering, Faculty of Engineering and Technology, University of Ilorin, Ilorin 1515, Nigeria
| | - Martin Ferguson-Pell
- Faculty of Rehabilitation Medicine, University of Alberta, 8205 114 St NW, Edmonton, AB T6G 2G4, Canada
| | - Kim Adams
- Faculty of Rehabilitation Medicine, University of Alberta, 8205 114 St NW, Edmonton, AB T6G 2G4, Canada
| | - Adriana Ríos Rincón
- Department of Occupational Therapy, Faculty of Rehabilitation Medicine, University of Alberta, 8205 114 St NW, Edmonton, AB T6G 2G4, Canada
| |
Collapse
|
3
|
Stuart L, Alford K, Vera JH. Non-pharmaceutical interventions for people living with HIV with cognitive impairment: A scoping review. PLoS One 2024; 19:e0314185. [PMID: 39585885 PMCID: PMC11588236 DOI: 10.1371/journal.pone.0314185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2024] [Accepted: 11/07/2024] [Indexed: 11/27/2024] Open
Abstract
BACKGROUND Cognitive impairment (CI) in HIV is often of multifactorial causation, and remains a prominent issue in the age of effective combination antiretroviral therapy (cART), affecting approximately 14% of people living with HIV. Despite the 2018 BHIVA directive stating the importance of commencing rehabilitation strategies in people living with HIV with CI, no types of cognitive rehabilitations or other non-pharmaceutical interventions are specifically recommended. This scoping review aimed to describe the types of and evidence relating to the non-pharmaceutical interventions which have been examined in people living with HIV with CI. METHODS Studies were identified from five electronic databases. Criteria for study inclusion were studies describing a non-pharmaceutical intervention published after 1st January 2000 in English, in a population of adults living with HIV with CI detected at baseline, without significant psychiatric or substance-misuse co-morbidity. RESULTS Fourteen studies met the criteria for inclusion, with the Frascati criteria most commonly used to define CI within participant populations. The median intervention length was 12 weeks (IQR = 6.5). Nine studies investigated interventions with some component of computerised cognitive training (CCT); other interventions included diet, exercise and goal management training. Studies most commonly examined neurocognitive outcomes, but also considered other outcomes including quality of life, depressive symptomatology, intervention acceptability and cART adherence. Eight studies observed improvement in cognition with CCT, with effects often maintained for several weeks post-intervention, however, results were not always statistically significant. Self-reported cognitive improvement and intervention acceptability was high amongst participants completing CCT. CONCLUSIONS There was heterogeneity across studies not only in intervention type, but in diagnostic tools used, the chosen outcome measures and cognitive batteries, making comparison difficult. Findings, however, indicate that CCT interventions may produce benefits in cognition and are acceptable to patients. Further research is required in larger samples, alongside identifying specific intervention components that improve outcomes.
Collapse
Affiliation(s)
- Lucinda Stuart
- Brighton and Sussex Medical School, Brighton, United Kingdom
| | - Kate Alford
- Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, United Kingdom
| | - Jamie H. Vera
- Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, United Kingdom
- University Hospitals Sussex, Brighton, United Kingdom
| |
Collapse
|
6
|
Ronold EH, Joormann J, Hammar Å. Computerized Working Memory Training in Remission From Major Depressive Disorder: Effects on Emotional Working Memory, Processing Speed, Executive Functions, and Associations With Symptoms. Front Behav Neurosci 2022; 16:887596. [PMID: 35832292 PMCID: PMC9272008 DOI: 10.3389/fnbeh.2022.887596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Accepted: 05/30/2022] [Indexed: 11/13/2022] Open
Abstract
Introduction Remission from major depressive disorder (MDD) is associated with residual symptoms related to reduced functioning, quality of life, and relapse risk. Previous studies have raised questions about mechanisms involved-in and affected by cognitive training. This study investigated the associations and changes among depressive symptoms, rumination, processing speed (PS), executive functioning (EF), and emotional working memory (e-WM) pre- post computerized working memory training (CWMT). Method Twenty-nine remitted participants were included in a pre- post pilot study of within-subject effects of online CWMT. A total of 20 participants completed the intervention and pre- post tests of EF and PS, e-WM, in addition to symptom and rumination measures. Associations between changes in symptoms and cognition were investigated pre- post. Associations between improvements in CWMT, depression history, and changes in cognition were explored. Hypotheses and statistics were preregistered before data were analyzed. Results Manipulation of negatively valanced stimuli in e-WM showed an inverse association with rumination pre-intervention, but the association disappeared post-intervention. Cognitive functioning improved in most conditions with largest effects in EF. Symptoms did not change in the remitted sample. CWMT improvements were related to improvements in some aspects of EF and PS, but also to worse self-reported attention. Depression history was related to less improvement in EF. Limitations Sample size was small and there was dropout from the study. There was no control group, thus precluding practice and placebo effects and causal relationships. Conclusions Computerized WM training improves cognitive functions and could influence associations between e-WM and rumination. This could counteract functional impairment following MDD.
Collapse
Affiliation(s)
- Eivind Haga Ronold
- Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway
- Division of Psychiatry, Haukeland University Hospital, University of Bergen, Bergen, Norway
| | - Jutta Joormann
- Department of Psychology, Yale University, New Haven, CT, United States
| | - Åsa Hammar
- Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway
- Division of Psychiatry, Haukeland University Hospital, University of Bergen, Bergen, Norway
| |
Collapse
|